Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $124,653.75 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25.
• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $79.45 on Friday. The firm’s fifty day moving average price is $69.41 and its 200 day moving average price is $69.42. Halozyme Therapeutics, Inc. has a 12 month low of $53.33 and a 12 month high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company has a market capitalization of $9.42 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 0.33 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the previous year, the company earned $1.11 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently made changes to their positions in HALO. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Harbour Investments Inc. grew its stake in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the period. Finally, Wexford Capital LP acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $70,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on HALO. Morgan Stanley decreased their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.